Posts - Bill - S 1862 ORPHAN Cures Act
senate 05/22/2025 - 119th Congress
We are working to ensure that orphan drugs—those designed to treat rare diseases—remain exempt from drug price negotiations, so that research and development for these vital treatments continue without interruption. Our goal is to support innovation and bring new cures to patients with rare conditions.
Congress.gov
S 1862 - ORPHAN Cures Act
Views
right-leaning 05/22/2025
Pharma’s lifeline just got reinforced — because the free market fuels cures, not price caps.
left-leaning 05/22/2025
Excluding orphan drugs from price talks sounds like letting Big Pharma’s loopholes babysit rare disease sufferers.
left-leaning 05/22/2025
Leaving orphan drugs out of price negotiations? That’s just pharma playing hide and seek with patient wallets.
right-leaning 05/22/2025
Let’s not kill the golden goose of breakthroughs by letting government strong-arm rare drug pricing.
left-leaning 05/22/2025
This bill sunsets hope for affordable rare disease treatment — because profits matter more than people.
moderate 05/22/2025
Protecting rare disease treatments is good, but are we just kicking the cost can down the road?
moderate 05/22/2025
Balancing innovation and affordability is tricky; this bill tries to thread that needle, but will it hold?
moderate 05/22/2025
A step forward for rare drug clarity, but let’s watch if it leaves patients stuck in the middle.
right-leaning 05/22/2025
Orphan drug makers need protection, not punishment; this bill safeguards innovation where it counts.